Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
HER2
Biotech
Zymeworks halts phase 2 ADC plans over 'clinical landscape'
Zymeworks has halted phase 2 plans for a HER2 antibody-drug conjugate while the biotech assesses the “evolving clinical landscape.”
James Waldron
Mar 7, 2024 9:00am
Endeavor signs $430M deal for Hummingbird's HER3-targeted ADC
Oct 19, 2023 10:29am
Jazz auditioning for new bandmates in hot M&A market
Jun 6, 2023 9:35am
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
May 31, 2023 9:45am
Byondis breast cancer drug fails to bloom as FDA denies approval
May 16, 2023 8:28pm
Roche pays $70M for HER2 breast cancer brain metastases prospect
May 9, 2023 6:30am